SBIR-STTR Award

Ultrafiltration membranes are being used widely by bio- and health-related research institutions as well as by biopharmaceutical industry for rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. Important medical applications include hemodialysis (treatment of end-stage renal failure) and open-heart surgery (blood oxygenation). In spite of the fact that a wide range of membranes with different specifications is available commercially, there is a strong need for improvement of membranes selectivity. The main approach to that is to narrow down pore size distribution, which is a challenge for the existing types of ultrafiltration membranes. This multi-phase Small Business Innovation Research project aims to develop and commercialize novel ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling. Such membranes are needed to fully realize the potential benefits of ultrafiltration in the processing of macromolecules of biological and medical interest. The targeted product - novel membranes - will be suitable as drop-in replacements of the state-of-the- art membranes in commercial membrane holders. The proposed development will drastically improve rapid purification and separation of natural products in biochemical and medical research and in medical care applications and thus is directly relevant to the mission of the National Institute Of General Medical Sciences. The main Phase I objective is to demonstrate feasibility of the proposed approach by fabricating and testing ultrafiltration membranes and confirming their enhanced performance versus commercial analogs. To ensure successful Phase II product development and Phase III commercialization, an early partnership has been secured with a developer of low-cost non-invasive glucose sensors.

Public Health Relevance:
The project addresses a significant problem in biomedical research and medical care: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The development of novel advanced ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling is proposed. The proposed technology will enable a novel family of high-performance membranes for use in biochemical analysis, laboratory studies, and, potentially, in hemodialysis for treatment of end-stage renal failure and in open heart surgery for blood oxygenation.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

This multi-phase SBIR project targets a significant problem within the mission of the National Institute of General Medical Sciences: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The main objective is to develop novel ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off (MWCO) and reduced fouling. Such membranes are needed to fully realize the potential benefits of ultrafiltration (UF) and thereby address various pressing needs in biochemical and medical research, medical care, bioanalysis and biomanufacturing. Synkera aims to addresses this challenge by developing and commercializing membranes made from self-organized nanoporous ceramic with practically monodisperse nanometer-scale pores. At the core of this approach, which was proven feasible in Phase I, is Synkera's unprecedented ability to precisely tune the membrane pore diameter to any value in the 0.5-150 nm range. All the key Phase I objectives have been met or exceeded. For the first time, Synkera fabricated prototypes of such membranes and demonstrated their superior performance in comparison with commercial membranes. A clear breakthrough opportunity is now open to develop a whole new family of UF membranes for a variety of applications with enormous market potential and technical, economical, and health benefits to the end users, consumers and patients. Not only do the new membranes offer a performance improvement for established UF uses, but the advanced architecture and unrivaled control of the structure of Synkera's membranes also potentially enable new breakthrough applications such as fractionation of complex macromolecule mixtures. To fully explore the potential of this technology, Synkera established collaborative R&D with several academic and industrial partners. The near-term products based on the proposed technology include planar UF filters that outperform currently available membranes, as well as application-specific membranes (e.g., for protein separation) and bioanalysis substrates (e.g., for glucose sensing). In partnership with OEM manufacturers of biomedical consumables, we will also develop and commercialize centrifuge, syringe and in-line filters, filter cartridges, multiwell-plate inserts, and UF modules. The main objective of Phase II is now to perform a systematic development of the membrane technology to meet the requirements of different applications, and advance it to a readiness level that enables inexpensive yet high-performance membranes and derivative products. , ,

Public Health Relevance:
The project addresses a significant problem in biomedical research and medical care: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The development of novel advanced ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling is proposed. The proposed technology will enable a novel family of high-performance membranes for use in biochemical analysis, laboratory studies, and, potentially, in hemodialysis for treatment of end-stage renal failure and in open heart surgery for blood oxygenation.

Thesaurus Terms:
Address;Alumina;Aluminum Oxide;Aluminum Oxide (Al2o3);Architecture;Area;Biochemical;Biologic Sciences;Biological;Biological Sciences;Biomanufacturing;Biomedical Research;Blood;Caliber;Cardiac Surgery;Cardiac Surgery Procedures;Cardiac Surgical Procedures;Care, Health;Caring;Cell Culture Techniques;Cells;Ceramic;Ceramics;Chemical Fractionation;Chemistry;Chromatography, Molecular Sieve;Colorado;Communities;Complement;Complement Proteins;Complex;Custom;D-Glucose;Development;Development And Research;Dextrose;Diagnostic;Diameter;Esrd;End Stage Renal Failure;End-Stage Kidney Disease;Engineering / Architecture;Ensure;Evaluation;Fracn;Family;Feedback;Fractionation;Fractionation Radiotherapy;Fungi, Filamentous;Glucose;Glycans;Goals;Government;Health Benefit;Healthcare;Hemodialyses;Hemodialysis;Hydrogen Oxide;Investigators;Investments;Laboratories;Laboratory Study;Letters;Life Sciences;Manufacturer;Manufacturer Name;Marketing;Medical;Medical Research;Membrane;Mission;Molds;Molecular Sieve Chromatography;Molecular Weight;Nigms;National Institute Of General Medical Sciences;Norway;Nucleic Acids;Patients;Performance;Persons;Phase;Polymers;Polysaccharides;Preparedness;Process;Proteins;R & D;R&D;Readiness;Renal Disease, End-Stage;Reproducibility;Research Personnel;Researchers;Reticuloendothelial System, Blood;Sbir;Sbirs (R43/44);Science Of Chemistry;Secure;Size Exclusion Chromatography;Small Business Innovation Research;Small Business Innovation Research Grant;Staging;Structure;Surface;Surgical Procedures, Heart;Switzerland;Syringes;Technology;Time;Tube;Ultrafiltration;Universities;Virus;Viruses, General;Water;Water Purification;Width;Work;Analog;Base;Bioimaging;Bioimaging/Biomedical Imaging;Biomedical Imaging;Commercialization;Cost;Falls;Gene Product;Heart Surgery;Industry Partner;Interest;Macromolecule;Meetings;Membrane Structure;Nano Meter Scale;Nano Meter Sized;Nano Scale;Nano Structured;Nanometer Scale;Nanometer Sized;Nanoscale;Nanostructured;Novel;Product Development;Prototype;Public Health Relevance;Research And Development